Zacks Research Has Positive Outlook for CORT Q3 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Investment analysts at Zacks Research increased their Q3 2025 EPS estimates for shares of Corcept Therapeutics in a research note issued on Wednesday, January 29th. Zacks Research analyst K. Das now anticipates that the biotechnology company will post earnings per share of $0.42 for the quarter, up from their previous forecast of $0.41. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.35 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q4 2025 earnings at $0.47 EPS, FY2025 earnings at $1.52 EPS and Q4 2026 earnings at $0.73 EPS.

CORT has been the subject of a number of other reports. StockNews.com lowered shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 25th. HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Corcept Therapeutics in a report on Thursday, October 31st. Canaccord Genuity Group boosted their price target on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a report on Thursday. Finally, Sandler O’Neill reaffirmed a “buy” rating on shares of Corcept Therapeutics in a research report on Friday, October 18th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $88.25.

Corcept Therapeutics Price Performance

Shares of CORT stock opened at $66.92 on Monday. Corcept Therapeutics has a 1-year low of $20.84 and a 1-year high of $71.29. The firm has a fifty day moving average of $56.02 and a two-hundred day moving average of $47.10. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. The firm has a market cap of $7.01 billion, a P/E ratio of 53.11 and a beta of 0.56.

Insiders Place Their Bets

In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.88, for a total transaction of $131,736.00. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Joseph Douglas Lyon sold 1,411 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $56.72, for a total transaction of $80,031.92. Following the sale, the insider now owns 8,494 shares in the company, valued at $481,779.68. This trade represents a 14.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 28,011 shares of company stock valued at $1,461,568 in the last 90 days. 20.50% of the stock is currently owned by insiders.

Institutional Trading of Corcept Therapeutics

Hedge funds have recently bought and sold shares of the stock. Kestra Investment Management LLC acquired a new stake in shares of Corcept Therapeutics in the fourth quarter valued at approximately $27,000. Braun Stacey Associates Inc. bought a new position in Corcept Therapeutics during the fourth quarter worth $14,935,000. Sanctuary Advisors LLC boosted its position in Corcept Therapeutics by 3.2% during the fourth quarter. Sanctuary Advisors LLC now owns 29,258 shares of the biotechnology company’s stock worth $1,474,000 after purchasing an additional 905 shares during the period. Principal Financial Group Inc. lifted its holdings in shares of Corcept Therapeutics by 4.4% during the fourth quarter. Principal Financial Group Inc. now owns 517,332 shares of the biotechnology company’s stock worth $26,068,000 after buying an additional 21,674 shares in the last quarter. Finally, Principal Securities Inc. lifted its holdings in shares of Corcept Therapeutics by 63.6% during the fourth quarter. Principal Securities Inc. now owns 1,243 shares of the biotechnology company’s stock worth $63,000 after buying an additional 483 shares in the last quarter. 93.61% of the stock is currently owned by institutional investors and hedge funds.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.